Hims stock dropped sharply Friday after the U.S. Food and Drug Administration said the shortage of widely-used weight-loss ...
Hims & Hers, one of the most popular telehealth services in the world, is in danger of losing one of its central revenue sources. The U.S. Food and Drug Administration (FDA) removed semaglutide ...
Hims & Hers Health (HIMS) shares nosedive on news from the US Food and Drug Administration (FDA) that the shortage in ...
Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...